TY  - JOUR
AU  - Morrison, Carl
AU  - Pabla, Sarabjot
AU  - Conroy, Jeffrey M
AU  - Nesline, Mary K
AU  - Glenn, Sean T
AU  - Dressman, Devin
AU  - Papanicolau-Sengos, Antonios
AU  - Burgher, Blake
AU  - Andreas, Jonathan
AU  - Giamo, Vincent
AU  - Qin, Moachun
AU  - Wang, Yirong
AU  - Lenzo, Felicia L
AU  - Omilian, Angela
AU  - Bshara, Wiam
AU  - Zibelman, Matthew
AU  - Ghatalia, Pooja
AU  - Dragnev, Konstantin
AU  - Shirai, Keisuke
AU  - Madden, Katherine G
AU  - Tafe, Laura J
AU  - Shah, Neel
AU  - Kasuganti, Deepa
AU  - de la Cruz-Merino, Luis
AU  - Araujo, Isabel
AU  - Saenger, Yvonne
AU  - Bogardus, Margaret
AU  - Villalona-Calero, Miguel
AU  - Diaz, Zuanel
AU  - Day, Roger
AU  - Eisenberg, Marcia
AU  - Anderson, Steven M
AU  - Puzanov, Igor
AU  - Galluzzi, Lorenzo
AU  - Gardner, Mark
AU  - Ernstoff, Marc S
PY  - 2018
DO  - 10.1186/s40425-018-0344-8
UR  - http://hdl.handle.net/10668/12439
T2  - Journal for immunotherapy of cancer
AB  - Immune checkpoint inhibitors (ICIs) have changed the clinical management of melanoma. However, not all patients respond, and current biomarkers including PD-L1 and mutational burden show incomplete predictive performance. The clinical validity and...
LA  - en
KW  - Algorithmic analysis
KW  - Borderline
KW  - Immune Desert
KW  - Inflamed
KW  - Ipilimumab
KW  - Nivolumab
KW  - Pembrolizumab
KW  - Adult
KW  - Aged
KW  - Aged, 80 and over
KW  - Female
KW  - Glucose-6-Phosphate Isomerase
KW  - Humans
KW  - Male
KW  - Melanoma
KW  - Middle Aged
KW  - Programmed Cell Death 1 Receptor
KW  - Skin Neoplasms
TI  - Predicting response to checkpoint inhibitors in melanoma beyond PD-L1 and mutational burden.
TY  - research article
VL  - 6
ER  -